AI Latest dispatch
A Nature Methods paper borrows the alignment method used to tune chatbots and applies it to protein design, producing a heat-stable H5N1 hemagglutinin with only 45 tries.
Everything else from the field.
A new preprint tests whether computational and AI forecasting models could have predicted the 2026 Bundibugyo Ebola epidemic in DR Congo before it became one of the largest on record. Here is what the models got right, what they missed, and why it matters for outbreak science.
Genentech validated the first AI-discovered neuroscience drug target from its $12B Recursion partnership. A proof point the AI-drug discovery field needed.
The August 2026 American Journal of Bioethics issue confronts AI agents moving into clinical and research operations, and asks an uncomfortable question: what happens when those same agents start doing the work of bioethicists?
On 5 August 2026, the FDA approved Moderna's mFLUSIVA, the first mRNA seasonal flu vaccine. The decision is small in label and large in consequence, because the same platform that produced COVID-19 shots in months can now be redirected to a pandemic influenza strain in weeks.
Jennifer Doudna's lab used an AI protein-design model to build a synthetic gene-editing enzyme, SynTnpB, that edits human cells nearly twice as efficiently as the natural version. Here is what the Science paper actually shows, and what it does not.
Biohub's open-source ESM models learned the rules of protein biology from evolution alone — and designed working drug binders in days. Here's what the release means, and where it falls short.
QED Science's AI ranked 57,455 bioRxiv preprints and named a 'top 1%'. Blinded experts sided with the machine over journal prestige in 75% of cases. We examine the evidence, the backlash, and what AI triage means for pandemic-era science.
Eli Lilly just wagered up to $2.75 billion on AI-designed medicines, yet not one AI-discovered drug has full FDA approval. Here's why 2026 is the year the field finally gets tested against clinical reality.
Insilico Medicine has pushed rentosertib, a drug whose target and molecule were both generated by AI, into a pivotal Phase III trial. It's the clearest test yet of whether AI drug discovery can produce medicines that work, not just headlines.
The first Bundibugyo Ebola vaccine reached human trials just 68 days into the DRC's largest-ever outbreak. What the sprint reveals about AI-era pandemic preparedness.
Stanford and Arc Institute researchers used genome language models to write complete bacteriophage genomes from scratch. Sixteen worked in the lab — and the result reopens a hard debate about AI biosecurity.
VirTues, a new foundation model published in Nature, learns one shared representation of spatial proteomics data across marker panels and imaging platforms—and finds biomarkers that predict immunotherapy response.
The Bundibugyo Ebola outbreak is now the largest in DRC history. With no licensed vaccine, three candidates have reached human trials in weeks — a real-world stress test of the 100 Days Mission, AI-assisted drug discovery and outbreak modelling.
Australia just logged its first H5N1 mass-mortality event. Here's how a new wave of AI tools — protein language models, generative antibody pipelines, AI-designed antigens — is being mobilised against the virus, and where the science still falls short.
August 2, 2026 was supposed to be the day the EU AI Act's toughest rules hit high-risk systems. Then the Digital Omnibus moved the goalposts. Here's what actually changed, and what it means for AI in drug discovery.
The Bipartisan Commission on Biodefense added AI as the first new technology priority to the Apollo Program since 2021. The technical evidence behind that decision comes from a red-team exercise in which AI-redesigned toxin sequences slipped past the screening software that DNA synthesis companies rely on.
The 2026 Bundibugyo epidemic is now the largest Ebola outbreak ever recorded in the DRC, against a virus for which no licensed vaccine or therapy exists. It is also the first serious field test of AI-era biology's central promise — and the results are more sobering, and more interesting, than the hype allows.
The US government's July 28 policy prohibits dangerous gain-of-function research outright. But purely computational design of novel biological agents is explicitly not prohibited — it gets an interagency monitoring group instead. Here's what the policy says, why the split matters, and what it doesn't tell us.
A new peer-reviewed study cut AI-redesigned toxin genes into fragments and fed them to four commercial DNA screening tools. Two caught fragments as short as 50 nucleotides. Here's what that means ten weeks before a US screening deadline — and why the authors are still worried.
